miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2

MicroRNAs (miRNAs) are short non-coding RNA molecules, which posttranscriptionally regulate genes expression and play crucial roles in diverse biological processes, such as development, differentiation, apoptosis, and proliferation. Here, we investigated the possible role of miRNAs in the development of multidrug resistance (MDR) in human gastric and lung cancer cell lines. We found that miR-497 was downregulated in both multidrug-resistant human gastric cancer cell line SGC7901/vincristine (VCR) and multidrug-resistant human lung cancer cell line A549/cisplatin (CDDP) and the downregulation of miR-497 was concurrent with the upregulation of BCL2 protein, compared with the parental SGC7901 and A549 cell lines, respectively. In vitro drug sensitivity assay demonstrated that overexpression of miR-497 sensitized SGC7901/VCR and A549/CDDP cells to anticancer drugs, respectively. The luciferase activity of BCL2 3′-untranslated region-based reporter constructed in SGC7901/VCR and A549/CDDP cells suggested that BCL2 was the direct target gene of miR-497. Enforced miR-497 expression reduced BCL2 protein level and sensitized SGC7901/VCR and A549/CDDP cells to VCR-induced and CDDP-induced apoptosis, respectively. Taken together, our findings first suggested that has-miR-497 could play a role in both gastric and lung cancer cell lines at least in part by modulation of apoptosis via targeting BCL2.

[1]  J Ma,et al.  MicroRNA and drug resistance , 2010, Cancer Gene Therapy.

[2]  R. Glasspool,et al.  Epigenetics as a mechanism driving polygenic clinical drug resistance , 2006, British Journal of Cancer.

[3]  Shaomeng Wang,et al.  Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. , 2003, Seminars in oncology.

[4]  Xia Shan,et al.  miR‐181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines , 2010, International journal of cancer.

[5]  J. Haier,et al.  MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. , 2010, European journal of cancer.

[6]  Hong-Ying Zhou,et al.  Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin , 2010, Medical oncology.

[7]  John C Reed,et al.  Drug Insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms , 2006, Nature Clinical Practice Oncology.

[8]  Zhiwei Wang,et al.  Implication of microRNAs in drug resistance for designing novel cancer therapy. , 2010, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[9]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[10]  C. Croce,et al.  MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. , 2007, JAMA.

[11]  Y. E. Chen,et al.  miR-497 regulates neuronal death in mouse brain after transient focal cerebral ischemia , 2010, Neurobiology of Disease.

[12]  H. Yamaue,et al.  Locoregional Chemotherapy for Patients with Pancreatic Cancer Intra-arterial Adjuvant Chemotherapy After Pancreatectomy with Portal Vein Resection , 2002, Pancreas.

[13]  K. Zhang,et al.  Glutathione-related mechanisms in cellular resistance to anticancer drugs. , 1998, International journal of oncology.

[14]  G. Wong,et al.  Hyaluronan-CD44 Interaction with Protein Kinase Cϵ Promotes Oncogenic Signaling by the Stem Cell Marker Nanog and the Production of MicroRNA-21, Leading to Down-regulation of the Tumor Suppressor Protein PDCD4, Anti-apoptosis, and Chemotherapy Resistance in Breast Tumor Cells* , 2009, The Journal of Biological Chemistry.

[15]  Tsung-Cheng Chang,et al.  Widespread microRNA repression by Myc contributes to tumorigenesis , 2008, Nature Genetics.

[16]  Peter T Nelson,et al.  The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases. , 2010, Journal of molecular biology.

[17]  H. Yamaue,et al.  Chemosensitivity testing of fresh human gastric cancer with highly purified tumour cells using the MTT assay. , 1992, British Journal of Cancer.

[18]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[19]  M. Volm,et al.  Intrinsic and Acquired Drug Resistance in Malignant Tumors , 2008, Arzneimittel-Forschung (Drug Research).

[20]  V. Ambros,et al.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.

[21]  D. Pompliano,et al.  Nat. Rev. Drug Disc. , 2007 .

[22]  Scott W. Lowe,et al.  Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.

[23]  Liu Hong,et al.  miR‐15b and miR‐16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells , 2008, International journal of cancer.

[24]  M. Dolan,et al.  Molecular mechanisms of resistance and toxicity associated with platinating agents. , 2007, Cancer treatment reviews.

[25]  Cheng He,et al.  MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme , 2009, Brain Research.

[26]  Jinghuan Li,et al.  Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma , 2009, Modern Pathology.

[27]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[28]  T. Fojo.  Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[29]  Xi Chen,et al.  Role of microRNA in anticancer drug resistance , 2010, International journal of cancer.